PV Bulletin

Melanotan II tanning peptide products found to be inconsistently dosed

TGA warns consumers against using Melanotan II tanning products due to inconsistent dosing.

Primary source: Safety monitoring and information

PV Impact Brief

Urgency: HighConfidence: high

What changed

The TGA has issued a warning to consumers against the use of Melanotan II tanning products after laboratory testing confirmed inconsistencies in dosing.

Why it matters

Inconsistent dosing of Melanotan II increases the risk of adverse health events in consumers, emphasizing the need for proper regulation and monitoring of unapproved therapeutic products.

Action needed

Organizations must enhance signal management processes to track and report adverse events related to Melanotan II products, ensuring compliance with safety regulations.

Relevant for
Medical Safety Lead
Processes impacted
Signal Management
Owner

Regulatory Intelligence Lead

Review cadence

Review in the next regulatory intelligence cycle.

Evidence and confidence

Confidence: highSource updated: Aug 17, 2026

Full briefing

Practical implication

Organizations must enhance signal management processes to track and report adverse events related to Melanotan II products, ensuring compliance with safety regulations.

The TGA has issued a warning against Melanotan II tanning products, highlighting significant health risks linked to inconsistent dosing as laboratory testing reveals variances in the amount of Melanotan II present in seized products.

What changed: The TGA has issued a warning to consumers against the use of Melanotan II tanning products after laboratory testing confirmed inconsistencies in dosing.

Why it matters: Inconsistent dosing of Melanotan II increases the risk of adverse health events in consumers, emphasizing the need for proper regulation and monitoring of unapproved therapeutic products.

Practical implication: Organizations must enhance signal management processes to track and report adverse events related to Melanotan II products, ensuring compliance with safety regulations.

View original source

  • Source: TGA Safety Alerts - Safety information
  • Published at source: 2026-08-17T22:16:00.000Z
  • Discovered by monitor: 2026-08-17T22:23:36.070Z

Published from the regulator source ingestion pipeline after PV impact triage.

#Safety Signal#Safety Signals#Australia#Source-ingestion#Regulator-monitor#Tga.gov.au

Related updates for your role

publicFDA · USA · Updated Sep 4, 2026

FDA Grants Accelerated Approval to Etcamah for Advanced Breast Cancer

Urgency: High

Regulatory teams must prepare for updating labeling to include details on the new indication and required diagnostic methods, along with planning for the confirmatory studies mandated by the FDA.

Signal ManagementLabelingRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicUK Health Security Agency · UK · Updated Sep 7, 2026

Low Flu Vaccination Rates Among Primary School Children

Urgency: High

Parents are reminded to complete and return flu vaccination consent forms promptly as vaccination sessions in schools are set to start this week, aiming for completion by late November.

Signal ManagementPV Quality Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: PV Quality Lead, Medical Safety Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicANSM (France) · France · Updated Sep 7, 2026Translated From French

Recall of Gore Viabahn Endoprosthesis with Bioactive Heparin Coating

Urgency: High

Health establishments receiving affected devices must be notified, and protocols established to ensure compliance with the recall.

Signal ManagementQPPV
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: QPPV, Medical Safety Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicANSM (France) · France · Updated Sep 7, 2026Translated From French

Atellica CH Revised C-Reactive Protein (RCRP) Safety Information - Siemens Healthcare Diagnostics

Urgency: High

Laboratories must implement the safety measures as indicated by the action registration number R2625739, effective from the notice date of September 7, 2026.

Signal ManagementQPPV
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: QPPV, Medical Safety Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward